Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 9/20 | 0.50 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.44 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.44 |
| ▸ | MTOR | P42345 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19858651 | 1.00 | TACR1 (0.50) | TACR1PDK1HDAC6HDAC11HDAC8 | |
| SCHEMBL18046715 | 0.78 | TACR1 (0.49) | TACR1PDK1HDAC6HDAC11HDAC8 | |
| SCHEMBL18046712 | 0.78 | TACR1 (0.49) | TACR1PDK1HDAC6HDAC11HDAC8 | |
| SCHEMBL30498677 | 0.74 | TACR1 (0.55) | TACR1PDK1HDAC6HDAC11HDAC8 | |
| SCHEMBL6410982 | 0.71 | HDAC6 (0.56) | TACR1PDK1HDAC6MTORALDH1A1 | |
| SCHEMBL5740118 | 0.70 | TACR1 (0.69) | TACR1KMT2A | |
| SCHEMBL29565828 | 0.69 | TACR1 (0.53) | TACR1PDK1HDAC6MTORKMT2A | |
| SCHEMBL10547820 | 0.69 | PDK1 (0.47) | TACR1PDK1HDAC6ALDH1A1KMT2A | |
| SCHEMBL21392795 | 0.68 | TACR1 (0.52) | TACR1PDK1HDAC6MTORALDH1A1 | |
| SCHEMBL24247623 | 0.68 | HDAC6 (0.55) | PDK1HDAC6HDAC11HDAC8ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180044282-A1 | ALPHA-CINNAMIDE COMPOUNDS AND COMPOSITIONS AS HDAC8 INHIBITORS | VALO EARLY DISCOVERY, INC. | 2018-02-15 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180044282-A1 | ALPHA-CINNAMIDE COMPOUNDS AND COMPOSITIONS AS HDAC8 INHIBITORS | HDAC8, HDAC7, HDAC1 | TACR1 4264/4885PDK1 1120/4885HDAC6 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.